More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$475750945
EPS
-0.96
P/E ratio
--
Price to sales
8.19
Dividend yield
--
Beta
0.656411
Previous close
$10.56
Today's open
$10.79
Day's range
$10.67 - $11.71
52 week range
$5.03 - $13.35
show more
CEO
Kevin J. Knopp
Employees
172
Headquarters
Burlington, MA
Exchange
NASDAQ Global Market
Shares outstanding
41333705
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
What 908 Devices (MASS) Said on Its Q3 Earnings Call
908 Devices NASDAQ: MASS reported record third-quarter revenue of $19 million, up 35% from a year earlier, and raised the low end of its 2026 revenue forecast as demand for its detection devices grew internationally.
MarketBeat • 9 hours ago

908 Devices Inc. (MASS) Q3 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q3 2026 Earnings Call Transcript
Seeking Alpha • 8 hours ago

908 Devices Reports Third Quarter 2026 Financial Results and Achieves Record Revenue
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended September 30, 2026. "We had a strong third quarter, driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record,” said Kevin J. Knopp, CEO and Co-founde.
Business Wire • 13 hours ago

908 Devices Inc. (MASS) Reports Q3 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.15 per share a year ago.
Zacks Investment Research • 11 hours ago

908 Devices to Participate in the Stifel 2026 Healthcare Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced that management will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, 2026 at 4:00 p.m. ET. A live webcast of the fireside chat will be available in the “Investors” section of the company's website at: www.908devices.c.
Business Wire • Nov 4, 2026

Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity
We initiated a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military. We initiated a position in Bowhead Specialty Holdings, a specialty insurer founded in 2020 by industry veteran Stephen Sills. We exited Coastal Financial in July. Our thesis rested on its role as a banking partner to fintech companies and the operating leverage those partnerships were expected to deliver this year.
Seeking Alpha • Oct 30, 2026

908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the third quarter 2026 before market open on Tuesday, November 10, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors”.
Business Wire • Oct 27, 2026

908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.908 Devices' management is scheduled to present at 3:45 p.m. Eastern Time. The presentation is webcast and interested parties can register for th.
Business Wire • Sep 1, 2026

908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
MarketBeat • Aug 30, 2026

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
MarketBeat • Aug 18, 2026

¹ Disclosures

Open an M1 investment account to buy and sell 908 Devices Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.